Sanofi's Dupixent Granted Priority Review by CDE for Adult Prurigo Nodularis Indication in China

Sanofi China's official WeChat account announced that on March 6, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration officially granted priority review status to Sanofi's Dupilumab Injection (trade name: Dupixent®, Chinese trade name: 达必妥®) for the treatment of adult prurigo nodularis. If approved, Dupixent will become the first and only targeted drug specifically for the treatment of prurigo nodularis in China.